Visão geral da empresa
A biotechnology firm, BioMarin Pharmaceutical Inc. is dedicated to the development and commercialization of advanced therapies designed to treat life-threatening rare diseases and various medical conditions across global markets, including the United States, Europe, Latin America, the Middle East, and the Asia Pacific. Operating within the healthcare sector specifically under the biotechnology industry, the company focuses on creating specialized pharmaceutical solutions rather than mass-market consumer goods. The entity maintains a substantial operational scale, employing 3221 individuals and holding a market capitalization of $11.00B, while generating annual revenue of $3.22B. These financial dimensions, particularly the $11.00B valuation relative to its $3.22B revenue stream, indicate a mature enterprise that commands significant market presence despite the niche nature of rare disease treatments, suggesting a robust foundation for long-term research and development expenditures.
Saúde financeira
The company reported a Trailing Twelve Months (TTM) revenue of $3.22B accompanied by a net income of $348.90M and an EBITDA of $722.89M. The substantial disparity between the $3.22B revenue figure and the $348.90M net income reveals a significant cost structure where operating expenses, including research, development, and general administrative costs, consume a large portion of top-line growth before reaching the bottom line. Free cash flow stands at $402.66M, which provides the organization with considerable financial flexibility to fund ongoing clinical trials, acquire assets, or expand manufacturing capabilities without immediate reliance on external capital markets. Profitability metrics further illustrate this structure, with a gross margin of 52.8% indicating efficient production costs relative to sales, an operating margin of 22.5% reflecting effective control over overheads, and a profit margin of 10.8% showing the final return after all expenses. Regarding liquidity and leverage, the balance sheet holds $1.56B in cash against $642.87M in debt, supported by a debt-to-equity ratio of 10.56, which suggests a leveraged position where equity capital exceeds debt obligations significantly. Short-term liquidity is exceptionally strong, evidenced by a current ratio of 5.21, implying the company possesses more than five times the current assets necessary to cover its current liabilities. Management effectiveness is quantified by a return on equity of 5.9% and a return on assets of 5.6%, metrics that indicate the capital deployed by the firm generates a moderate return, consistent with the high-investment nature of the biotechnology sector.
Avaliação de valorização
Valuation multiples for BioMarin Pharmaceutical Inc. show a trailing P/E ratio of 31.78 compared to a forward P/E of 8.49. The stark divergence between the trailing P/E of 31.78 and the forward P/E of 8.49 implies that the market expects a significant increase in future earnings, as investors are pricing in substantial growth that will compress the valuation multiple over time. The price-to-book ratio is recorded at 1.81, indicating that the stock trades at a premium of 81% over its tangible book value, which is typical for intellectual property-heavy biotechnology firms where future potential is valued above historical asset costs. Alternative valuation metrics provide additional context, with a price-to-sales ratio of 3.42 and an EV/EBITDA of 13.95, suggesting the company is valued at roughly 14 times its earnings before interest, taxes, depreciation, and amortization, a multiple that aligns with high-growth healthcare peers. Price action over the last year shows a 52-week high of $66.28 and a 52-week low of $50.76. Without a specific current price provided in the available facts to calculate an exact percentage, the trading range establishes a volatility corridor where the asset has fluctuated between these specific bounds. The beta value is 0.29, which indicates that the stock price exhibits significantly lower volatility relative to the broader market, moving with only about 29% of the intensity of the overall index.
Growth & Income
Revenue growth year-over-year stands at 17.0%, while earnings growth year-over-year is listed as N/A. The absence of a specific earnings growth rate figure precludes a direct numerical comparison of earnings speed versus revenue speed, though the robust 17.0% revenue expansion highlights strong top-line traction in its rare disease portfolio. As the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute dividends to shareholders. This lack of dividend distribution indicates that BioMarin Pharmaceutical Inc. retains all of its earnings to reinvest into research and development programs and commercial expansion rather than providing immediate income to investors. The overall growth and income profile is characterized by aggressive revenue expansion funded entirely through retained earnings, offering potential capital appreciation but no current income stream for investors seeking dividend yields.